From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
|Articles|April 18, 2012
Express Scripts' 2011 Drug Trend Report Is Available Now
Express Scripts recently announced that their new Drug Trend Report is available for download.
Advertisement
The 2011 Drug Trend Report from Express Scripts is now available for download,
Here’s a sneak peek at the topics discussed in the new Drug Trend Report:
- New insights into nonadherence
- Innovative solutions for enhanced patient care
- 2011 industry review
- Changes in prescription drug spending in 2011
- In-depth review of traditional and specialty medications
- Forecast of traditional and specialty medications
- Medicare and Medicaid overview, challenges, solutions, and trends
- Analysis of the top three traditional therapy classes - inflammatory conditions, multiple sclerosis, and cancer
The report is full of tidbits regarding specialty drug trends and forecasts. This is a
Advertisement
Related to this article
From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
5